Supply and Delivery of Human Seasonal Trivalent Influenza Vaccines

The HSE wishes to invite Tender Submissions for the supply of up to 1.25 million doses of Human Seasonal Trivalent Influenza Vaccines for the 2025/2026 season. The requirement for Human Seasonal Trivalent Influenza Vaccines can include Cell Based, Egg Based or Recombinant Vaccines. The HSE reserves the right to award a portion of the total tendered dose amount to cohort specific vaccines. The HSE will confirm its requirements after evaluation, at Contract stage. Tenderers should include provision for an additional 200,000 doses or 16 percent of the potential awarded quantity as a contingency stock.